Today marked a milestone moment for Sironax. We celebrated recent transformative achievements – the strategic expansion of our US team and IND approvals from China CDE. These are pivotal steps that position us to accelerate global development while staying root-ed in groundbreaking science.
At Sironax, we tackle the hardest problems in degenerative diseases. We are deeply proud of our team’s relentless pursuit of innovation, having successfully advanced several FIC/BIC candidates into clinical development. Standing at this turning point, we’re closer than ever to a future where once-inevitable diseases are no longer a threat, and disease-modifying ther-apies transform lives of millions of patients and their families.
“The future is not written—it is ours to create.”
With a strengthened global footprint and a pipeline of FIC/BIC assets, we’re poised to rede-fine what’s possible.
About Sironax
Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs focusing on key mechanisms underlying age-related degenerative diseases, including dysregulated cellular death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax is currently conducting clinical studies with SIR2501, SIR4156, and SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups.
Contact Information
Investors / Media
Erik Kopp
Executive Director, Corporate Communications and Investor Relations
Business Development
Libin Shang, Ph.D.
Vice President, Business Development, Public Affairs and Beijing Operations